Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell™ for Treatment of COPD
Therapeutic Solutions International announced advancements in its COPD program alongside a pivotal COVID-19 clinical trial.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
In a series of experiments, mice were treated with JadiCells, Myeloid Derived Suppressor Cells, and a combination of the two. It was found that the combination possessed superior ability to reduce lung damage and stimulate pulmonary regeneration. Additionally, administration of the FDA cleared drug Leukine was demonstrated to naturally increase levels of Myeloid Derived Suppressor cells and enhance activity of the JadiCells.
“As a medical doctor that routinely sees the devastation caused by COPD, I am extremely excited about the possibility of curing this disease” said Dr.
The Company recently filed an Investigational New Drug application for using its Phase III stem cells, called JadiCells, for treatment of COPD1.
“These recent data are a result of our multidisciplinary approach to chronic diseases. Since there is an immunological mechanism at play here, we are currently in discussion with several immunotherapy stakeholders for collaborations and partnerships” said
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005565/en/
ir@tsoimail.com
Source: